BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ANS02 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ANS02\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07538804-2347@assetmemo.bio
DTSTAMP:20261121T004527Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:ANS02: Phase 1/2 readout est. (NCT07538804)
DESCRIPTION:ANS02\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Smal
 l Cell Lung Cancer\nEstimated primary completion: 30 June 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ans02#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07538804
URL:https://assetmemo.bio/drug/ans02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
